Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of BPR-101 capsules for bacterial vaginosis
CTR20243445Phase 2Completed
- Sponsor
- Chengdu Better Pharmaceutical
- Start
- Sep 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BPR-101 in bacterial vaginosis (BV) (2 arms), sponsored by Chengdu Better Pharmaceutical. Primary endpoint: Clinical cure rate. Started Sep 2024; status: completed.
02
Drugs
BPR-101
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on CTR20243445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243445.